Decrease in HBsAg After TAF Switching from Entecavir During Long-Term Treatment of Chronic Hepatitis B Virus Infection
Achieving HBsAg seroclearance is a key goal in treating chronic hepatitis B virus (HBV) infection but remains difficult with nucleos(t)ide analogues (NAs). Tenofovir alafenamide fumarate (TAF), a recommended NA for managing chronic HBV infection (CHB), has uncertain effects on HBsAg levels and poten...
Saved in:
Main Authors: | Kazuto Tajiri, Yuka Hayashi, Aiko Murayama, Nozomu Muraishi, Masami Minemura, Ichiro Yasuda |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2024-12-01
|
Series: | Viruses |
Subjects: | |
Online Access: | https://www.mdpi.com/1999-4915/17/1/44 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
基因工程乙肝疫苗的研制——Ⅲ.MT-5细胞的HBsAg纯化与鉴定
Published: (1990-01-01) -
两孔一步法同时检测HBsAg与抗-HBs的ELISA技术
Published: (1989-01-01) -
Observational pilot study of switching from entecavir to tenofovir alafenamide in patients with chronic hepatitis B
by: Takuya Matsubara, et al.
Published: (2025-01-01) -
慢性HBV 感染者血清HBsAg 自发转阴的影响因素分析
by: 陈兴, et al.
Published: (2018-01-01) -
慢性HBV感染者核苷(酸)类似物长期治疗HBsAg转阴的影响因素
by: 李向永, et al.
Published: (2018-01-01)